BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsPartnership

Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashes This common and often overlooked condition is characterized by eyelid redness, itching and crusting, and the collaboration encourages people

Related news

TARSTarsus Pharmaceuticals2026-03-23 12:30 EST

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

TARSTarsus Pharmaceuticals2026-05-06 20:05 EST

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

OCGNOcugen2026-07-13 11:02 EST

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

PRQRProQR Therapeutics2026-04-08 12:00 EST

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

IRIXIRIDEX2026-04-07 20:05 EST

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Stock data

Close
65.33 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States